English
Regional settings| Spread | 0.0050 | ||||
 Long position overnight feeLong position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | -0.026179% | ||||
| Short position overnight fee Short position overnight fee
Trade size with leverage ~ $5,000.00 Short position overnight fee ~ $4,000.00 | 0.003957% | ||||
| Overnight fee time | 21:00 (UTC) | ||||
| Currency | USD | ||||
| Min traded quantity | 1 | ||||
| Margin | 20 | ||||
| Stock exchange | United States of America | ||||
| Commission on trade1 | 0% |
1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information
| Prev. Close | 0.2463 |
| Open | 0.2433 |
| 1-Year Change | -61.13% |
| Day's Range | 0.2433 - 0.2471 |
Asensus Surgical (ASXC) is a medical device company that engages in digitising the interface between the surgeon and the patient to improve minimally invasive surgery (MIS).
Founded in 2006, Asensus is headquartered in Durham, North Carolina. It pioneers a new era of performance-guided surgery, using advanced capabilities, like machine vision, augmented intelligence, connectivity and robotics in laparoscopy.
Asensus has built the foundation of Digital Laparoscopy with the help of its Senhance Surgical System powered by the Intelligent Surgical Unit (ISU) to address clinical, cognitive and economic shortcomings in surgery.
The Senhance Surgical System is a multi-port robotic system that provides enhanced control with surgeon eye-tracking camera control & 3D (three dimensional) HD (high definition) vision and enhances precision through tremor filtrations and robotic stabilisation. Additionally, surgeons can have enhanced focus during surgery through Asensus’s optimised ergonomics and the sense of touch (haptics).
The surgical device that consists of a robotic instrument and a camera for laparoscopic procedures is considered to be the smallest instrument offered in robotics, leading to smaller incisions than traditional robotic surgery. Asensus’ Senhance ultrasonic system is an advanced energy device to deliver controlled energy to ligate and divide tissue.
Asensus Surgical previously developed the SPIDER device and the SurgiBot System. It changed its name from TransEnterix in February 2021. The company went public as TransEnterix in May 2014. It trades on the NYSE American under the ticker ‘ASXC’.
